Кирены — прямые ингибиторы ренина — новый класс лекарственных средств. Потенциальные возможности клинического применения

Ссылки

• 1. Abassi Z., Armaly Z., Nakhoul F. et al. (2008) Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension. Harefuah, 147(6): 536–542.
• 2. Anderson P.W., Do Y.S., Hsueh W.A. (1993) Angiotensin II causes mesangial cell hypertrophy. Hypertension, 21(1): 29–35.
• 3. Aoki H., Izumo S., Sadoshima J. (1998) Angiotensin II activates RhoA in cardiac myocytes: a critical role of RhoA in angiotensin II-induced premyofibril formation. Circ. Res., 82(2): 666–676.
• 4. Atlas S.A. (2007) The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J. Manag. Care Pharm., 13(Suppl B): 9–20.
• 5. Azizi M., Ménard J., Bissery A. et al. (2004) Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J. Am. Soc. Nephrol., 15(12): 3126–3133.
• 6. Azizi M., Webb R., Nussberger J., Hollenberg N.K. (2006) Renin inhibition with aliskiren: where are we now, and where are we going? J. Hypertens., 24(2): 243–256.
• 7. Baker K.M. Aceto J.F. (1990) Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am. J. Physiol., 259(2 Pt 2): Н610–Н618.
• 8. Batenburg W.W., Danser A.J. (2008) Prorenin and the (pro)renin receptor: binding kinetics, signalling and interaction with aliskiren. J. Renin Angiotensin Aldosterone Syst., 9(3): 181–184.
• 9. Bauer J.H., Reams G.P. (1995) The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs. Arch. Intern. Med., 155(13): 1361–1368.
• 10. Berk B.C., Corson M.A. (1997) Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Circ. Res., 80(5): 607–616.
• 11. Berman N., Hostetter T. (2008) Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension. Am. J. Kidney Dis., 51: 370–372.
• 12. Border W.A., Noble N.A. (1998) Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension, 31(1 Pt 2): 181–188.
• 13. Border W.A., Ruoslahti E. (1992) Transforming growth factor-beta in disease: the dark side of tissue repair. J. Clin. Invest., 90(1): 1–7.
• 14. Brown M.J. (2008) Aliskiren. Circulation, 118(7): 773–784.
• 15. Brunner H.R., Gavras H., Laragh J.H. et al. (1974) Hypertension in man. Exposure of the renin and sodium components using angiotensin II blockade. Circ. Res., 24 (Suppl I): I35–I43.
• 16. Casas J.P., Chua W., Loukogeorgakis S. et al. (2005) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet, 366(9502): 2026–2033.
• 17. Chawla P.S., Kochar M.S. (2008) What’s new in clinical pharmacology and therapeutics. WMJ, 107(2): 76–83.
• 18. Dahlöf B., Devereux R.B., Kjeldsen S.E. et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 359(9311): 995–1003.
• 19. Dahlöf B., Sever P.S.; Poulter N.R. et al. (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT BPLA): a multicentre randomised controlled trial. Lancet, 366(9489): 895–906.
• 20. Danser A.J., Nguyen G. (2008) The Renin Academy Summit: advancing the understanding of renin science. J. Renin Angiotensin Aldosterone Syst., 9(2): 119–123.
• 21. Daugherty K.K. (2008) Aliskiren. Am. J. Health Syst. Pharm., 65(14): 1323–1332.
• 22. de Gasparo M., Cumin F., Nussberger J. et al. (1989) Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers. Br. J. Clin. Pharmacol., 27(5): 587–596.
• 23. Dieterich H., Kemp C., Vaidyanathan S. et al. (2006) Aliskiren, the first in a new class of orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteers. Clin. Pharmacol. Ther., 79(64): 111–124.
• 24. Dieterle W., Corynen S., Mann J. (2004) Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br. J. Clin. Pharmacol., 58(4): 433–436.
• 25. Dieterle W., Corynen S., Vaidyanathan S., Mann J. (2005) Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int. J. Clin. Pharmacol. Ther., 43(11): 527–535.
• 26. Dietz R., Dechend R., Yu C.M., Bheda M. et al. (2008) Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension1. J. Renin Angiotensin Aldosterone Syst., 9(3): 163–175.
• 27. Dostal D.E., Booz G.W., Baker K.M. (1996) Angiotensin II signalling pathways in cardiac fibroblasts: Conventional versus novel mechanisms in mediating cardiac growth and function. Mol. Cell. Biochem., 157(1–2): 15–21.
• 28. Duff J.L., Berk B.C., Corson M.A. (1992) Angiotensin II stimulates the pp44 and pp42 mitogen-activated protein kinases in cultured rat aortic smooth muscle cells. Biochem. Biophys. Res. Commun., 188(1): 257–264.
• 29. Dzau V.J. (2001) Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension, 37(4): 1047–1052.
• 30. Everett A.D., Tufro-McReddie A., Fisher A. et al. (1994) Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression. Hypertension, 23(5): 587–592.
• 31. Fisher N.D., Hollenberg N.K. (2005) Renin inhibition: what are the therapeutic opportunities? J. Am. Soc. Nephrol., 16(3): 592–529.
• 32. Flather M.D., Yusuf S., Kober L. et al. (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet, 355(9215): 1575–1581.
• 33. Fukamizu A., Sugimura K., Takimoto E. et al. (1993) Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J. Biol. Chem., 268(16): 11617–11621.
• 34. Gaddam K.K., Oparil S. (2008) Renin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients? Curr. Opin. Nephrol. Hypertens., 17(5): 484–490.
• 35. Ganten D., Wagner J., Zeh K. et al. (1992) Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc. Natl. Acad. Sci. USA, 89(16): 7806–7810.
• 36. Geisterfer A.A., Peach M.J., Owens G.K. (1988) Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ. Res., 62: 749–756.
• 37. Gore J.M. (2008) Beyond Blood Pressure Control: Targeting Proteinuria with Renin-Angiotensin-Aldosterone Inhibitors. J. Watch Cardiology, 14(7): 54.
• 38. Gradman A.H., Kad R. (2008) Renin inhibition in hypertension. J. Am. Coll. Cardiol., 51(5): 519–528.
• 39. Gradman A.H., Schmieder R.E., Lins R.L. et al. (2005) Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation, 111(8): 1012–1018.
• 40. Gross F., Lazar J., Orth H. (1972) Inhibition of the renin-angiotensinogen reaction by pepstatin. Science, 175(22): 656.
• 41. Habibi J., Whaley-Connell A., Hayden M.R. et al. (2008) Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology, 149(11): 5643–5653.
• 42. Herron J., Mitchell J., Oh B. et al. (2006) The novel renin inhibitor aliskiren is not associated with rebound effects on blood pressure or plasma renin activity following treatment withdrawal. J. Clin. Hypertens., 8 (Suppl. A): A86.
• 43. Hollenberg N.K., Fisher N.D., Price D.A. (1998) Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension, 32(3): 387–392.
• 44. Imanishi T., Tsujioka H., Ikejima H. et al. (2008) Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension, 52(3): 563–72.
• 45. Ingelfinger J.R. (2008) Aliskiren and dual therapy in type 2 diabetes mellitus. N. Engl. J. Med., 358(23): 2503–2505.
• 46. Jensen C., Herold P., Brunner H.R. (2008) Aliskiren: the first renin inhibitor for clinical treatment. Nat. Rev. Drug Discov., 7(5): 399–410.
• 47. Jordan J., Engeli S., Boye S.W. et al. (2007) Direct Renin inhibition with аliskiren in obese patients with arterial hypertension. Hypertension, 49(5): 1047–1055.
• 48. Julius S., Kjeldsen S.E., Weber M. et al.; VALUE trial group (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 363(9426): 2022–31.
• 49. Kapoor S. (2008) Aliskiren: a rapidly, expanding role in the management of recalcitrant hypertension and renal disease. Int. Urol. Nephrol., 40(4): 1115–1116.
• 50. Kario K., Pickering T.G., Umeda Y. et al. (2003) Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation, 107(10): 1401–1406.
• 51. Kelly D.J., Zhang Y., Moe G. et al. (2007) Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia, 50(11): 2398–2404.
• 52. Kim S., Iwao H. (2000) Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol. Rev., 52(1): 11–34.
• 53. Kleinbloesem C.H., Weber C., Fahrner E. et al. (1993) Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects. Clin. Pharmacol. Ther., 53(5): 585–592.
• 54. Kobori H., Nangaku M., Navar L.G. et al. (2007) The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev., 59(3): 251–287.
• 55. Krop M., Garrelds I.M., de Bruin R.J. et al. (2008) Aliskiren accumulates in Renin secretory granules and binds plasma prorenin. Hypertension, 52(6): 1076–1083.
• 56. Krum Н. (2008) Role of renin in heart failure and therapeutic potential of direct renin inhibition. J. Renin Angiotensin Aldosterone Syst., 9(3): 177–180.
• 57. Kushiro T., Itakura H., Abo Y. et al. (2006) Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens. Res., 29(12): 997–1005.
• 58. McMurray J.V. (2000) AT1 receptor antagonists — beyond blood pressure control: possible place in heart failure treatment. Heart; 84(Suppl 1): i42–i45.
• 59. McMurray J.V., Pitt B., Latini R. et al. (2008) Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail., 1: 17–24.
• 60. Menard J., Boger R.S., Moyse D.M. et al. (1995) Dose-dependent effects of the renin inhibitor zankiren HCI after a single oral dose in mildly sodium-depleted normotensive subjects. Circulation, 91(2): 330–338.
• 61. Morsing P., Adler G., Brandt-Eliasson U. et al. (1999) Mecha­nistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension, 33(6): 1406–1413.
• 62. Müller D.N., Luft F.C. (2006) Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin. J. Am. Soc. Nephrol., 1(2): 221–228.
• 63. Musini V.M., Fortin P.M., Bassett K. et al. (2008) Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst. Rev., (4): CD007066.
• 64. Nguyen G., Delarue F., Burcklé C. et al. (1996) Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int., 50(6): 1897–1903.
• 65. Nguyen G., Delarue F., Burcklé C. et al. (2002) Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest., 109(11): 1417–27.
• 66. Nussberger J., Wuerzner G., Jensen C. et al. (2002) Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension, 39(1): E1–8.
• 67. O’Brien E. (2006) Aliskiren: a renin inhibitor offering a new approach for the treatment of hypertension. Expert Opin. Investig Drugs., 15(10): 1269–1277.
• 68. O’Brien E., Barton J., Nussberger J. et al. (2007) Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension, 49(2): 276–284.
• 69. Oh B.H., Mitchell J., Herron J.R. et al. (2007) Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J. Am. Coll. Cardiol., 49(11): 1157–63
• 70. Oparil S., Yarows S.A., Patel S. et al. (2007) Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet, 370(9583): 221–229.
• 71. Parving H.H., Persson F., Lewis J.B. et al. (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med., 358(23): 2433–2446.
• 72. Persson F., Rossing P., Schjoedt K.J. et al. (2008) Time course of antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int., 73(12):1419–1425.
• 73. Pilz B., Shagdarsuren E., Wellner M. et al. (2005) Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension, 46(3): 569–576.
• 74. Pimenta E., Oparil S. (2008) Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering? Cardiol. Clin., 26(4):527–535.
• 75. Pool J.L., Schmieder R.E., Azizi M. et al. (2007) Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am. J. Hypertens., 20(1): 11–20.
• 76. Rashid H. (2008) Direct renin inhibition: an evaluation of the safety and tolerability of aliskiren. Curr. Med. Res. Opin., 24(9): 2627–2637.
• 77. Rongen G.A., Lenders J.W., Smits P. et al. (1995) Clinical pharmacokinetics and efficacy of renin inhibitors. Clin. Pharmacokinet., 29(1): 6–14.
• 78. Ruggenenti P., Perna A., Gherardi G. et al. (1999) Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet, 354(9176): 359–364.
• 79. Saijonmaa O., Fyhrquist F. (2008) Can aliskiren reduce the incidence of cough caused by ramipril? J. Renin Angiotensin Aldosterone Syst., 9(3): 176.
• 80. Schefe J.H., Neumann C., Goebel M. et al. (2008) Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by aliskiren. J. Hypertens., 26(9): 1787–1794.
• 81. Schernthaner G. (2008) Dual inhibition with losartan and aliskiren: a promising therapeutic option for type 2 diabetic nephropathy? Nat. Clin. Pract. Nephrol., 4(12): 656–657.
• 82. Schunkert H., Sadoshima J., Cornelius T. et al. (1995) Angiotensin II–induced growth responses in isolated adult rat hearts: Evidence for load-independent induction of cardiac protein synthesis by angiotensin II. Circ Res.; 1995 76(3): 489–497.
• 83. Schwartz K., Chassagne C., Boheler K.R. (1993) The molecular biology of heart failure. J. Am. Coll. Cardiol., 22(4 Suppl A): 30A–33A.
• 84. Sealey J.E., Laragh J.H. (2008) Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. Am. J. Hypertens., 22(1): 112–121.
• 85. Segall L., Covic A., Goldsmith D.J. (2007) Direct renin inhibitors: the dawn of a new era, or just a variation on a theme? Nephrol. Dial. Transplant., 22(9): 2435–2439.
• 86. Siamopoulos K.C., Kalaitzidis R.G. (2008) Inhibition of the renin-angiotensin system and chronic kidney disease. Int. Urol. Nephrol., 40(4): 1015–1125.
• 87. Sica D., Gradman A.Н., Lederballe O. et al. (2006) Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52-weeks) treatment of hypertension. Eur. Heart J., 27(Abstract Suppl):121 P797.
• 88. Simon G. Altman S. (1992) Subpressor angiotensin II is a bifunctional growth factor of vascular muscle in rats. J. Hypertension, 10(10): 1165–1171.
• 89. Singh V.P., Le B., Khode R. et al. (2008) Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes, 57(12): 3297–3306.
• 90. Skeggs L.T., Kahn J.R., Lentz K.E. et al. (1957) Preparation, purification, and amino acid sequence of a polypeptide renin substrate. J. Exp. Med., 106: 439–453.
• 91. Solomon S., Appelbaum E., Manning W.J. et al. (2008) Effect of the direct renin inhibitor aliskiren, either alone or in combination with losartan, compared to losartan, on left ventricular mass in patients with hypertension and left ventricular hypertrophy: the Aliskiren Left Ventricular Assessment of Hypertrophy (ALLAY) Trial. Late Breaker presentation at American College of Cardiology, 57th Scientific Sessions.
• 92. Staessen J.A., Li Y., Richart T. (2006) Oral renin inhibitors. Lancet, 368(9545): 1449–1456.
• 93. Staessen J.A., Li Y., Thijs L. et al. (2005) Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens. Res., 28(5): 385–407.
• 94. Stanton A. (2003) Therapeutic potential of renin inhibition in the management of cardiovascular disorders. Am. J. Cardiovasc. Drugs, 3(6): 389–394.
• 95. Stanton A., Jensen C., Nussberger J. et al. (2003) Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension, 42(6): 1137–1143.
• 96. Strasser R.H., Puig J.G., Farsang C. et al. (2007) A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J. Hum. Hypertens., 21(10): 780–787.
• 97. Tan L.B., Jalil J.E., Pick R. et al. (1991) Cardiac myocyte necrosis induced by angiotensin II. Circ. Res., 69(5): 1185–1195.
• 98. Tato A.M., García López F. (2008) Is the combination aliskiren /valsartan as effective and safe as either drug in monotherapy for treating hypertension? Nefrologia, 28(Suppl 2):10–11.
• 99. Timmermans P.B., Wong P.C., Chiu A.T. et al. (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev., 45(2): 205–251.
• 100. Triller D.M., Evang S.D., Tadrous M. et al. (2008) First renin inhibitor, aliskiren, for the treatment of hypertension. Pharm. World Sci., 30(6):741–749.
• 101. Turnbull F. (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, 362(9395): 1527–1535.
• 102. Tuttle K.R. (2009) Could renin inhibition be the next step forward in the treatment of diabetic kidney disease? Nat. Clin. Pract. Endocrinol. Metab., 5(1): 20–21.
• 103. Unger T. (2001) Inhibiting rennin-angiotensin in the brain: the possible therapeutic implications. Blood Press. Suppl., 1: 12–16.
• 104. Vaidyanathan S., Bartlett M., Dieterich H.A. et al. (2008) Pharmacokinetic interaction of the direct Renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects. Cardiovasc Ther. 26(4): 238–246.
• 105. Vaidyanathan S., Camenisch G., Schuetz H. et al. (2008) Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J. Clin. Pharmacol., 48(11):1 323–1338.
• 106. Vaidyanathan S., Jermany J., Yeh C. et al. (2006) Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br. J. Clin. Pharmacol., 62(6): 690–698.
• 107. Vaidyanathan S., Maboudian M., Warren V. et al. (2008) A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects. Curr. Med. Res. Opin., 24(8): 2313–2326.
• 108. Vaidyanathan S., Reynolds C., Yeh C.M. et al. (2007) Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J. Clin. Pharmacol., 47(4): 453–460.
• 109. Vaidyanathan S., Valencia J., Kemp C. et al. (2006) Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int. J. Clin. Pract., 60(11): 1343–1356.
• 110. Vaidyanathan S., Warren V., Yeh C. et al. (2007) Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment. Clin. Pharmacol., 47(2): 192–200.
• 111. Verma S., Gupta M.K. (2008) Aliskiren improves nitric oxide bioavailability and limits atherosclerosis. Hypertension, 52(3): 467–469.
• 112. Villamil A., Chrysant S., Calhoun D. et al. (2006) The novel renin inhibitor aliskiren provides effective blood pressure control in patients with hypertension when used alone or in combination with hydrochlorothiazide. J. Clin. Hypertens., 8 (Suppl A): A100.
• 113. Wang J.G., Staessen J.A., Franklin S.S. et al. (2005) Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension, 45(5): 907–913.
• 114. Watanabe T., Barker T.A., Berk B.C. (2005) Angiotensin II and the endothelium: diverse signals and effects. Hypertension, 45(2): 163–169.
• 115. Weber K.T. (1997) Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation, 96(11): 4065–4082.
• 116. Weir M., Bush C., Zhang J. et al. (2006) Antihypertensive efficacy and safety of the oral renin inhibitor aliskiren in patients with hypertension: a pooled analysis. Eur. Heart. J., 27 (Abstract Suppl): 299.
• 117. Westermann D., Riad A., Lettau O. et al. (2008) Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension. 52(6): 1068–1075.
• 118. Williams B. (2008) The year in hypertension. J. Am. Coll. Cardiol., 51(18): 1803–1817.
• 119. Wolf G., Ziyadeh F.N. (1997) The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am. J. Kidney Dis., 29(1): 153–163.
• 120. Wood J.M., Maibaum J., Rahuel J. et al. (2003) Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun., 308(4): 698–705.
• 121. Wood J.M., Schnell C.R., Cumin F. et al. (2005) Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J. Hypertens., 23(2): 417–426.
• 122. Yamada T., Horiuchi M., Dzau V.J. (1996) Angiotensin II type 2 receptor mediates programmed cell death. Proc. Natl. Acad. Sci. USA, 93(1): 156–160.
• 123. Zaman M.A., Oparil S., Calhoun D.A. (2002) Drugs targeting the renin-angiotensin-aldosterone system. Nat. Rev. Drug Discov., 1(8): 621–636.
• 124. Zhao C., Vaidyanathan S., Yeh C.M. et al. (2006) Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin. Pharmacokinet., 45(11): 1125–34.
• 125. Zou Y., Komuro I., Yamazaki T. et al. (1998) Cell type-specific angiotensin II-evoked signal transduction pathways: critical roles of G-beta-gamma subunit, Src family, and Ras in cardiac fibroblasts. Circ. Res., 82(3): 337–345.